Broad Spectrum HPV (Human Papillomavirus) Vaccine in 16 to 26 Year Old Women (V505-001)
The purpose of this study is to evaluate the safety and immunogenicity of V505 in comparison to GARDASIL (TM)
Cervical Cancer|Vulvar Cancer|Vaginal Cancer|Genital Warts|Human Papillomavirus Infection
BIOLOGICAL: Comparator: V505 formulation 1|DRUG: Comparator: V505 formulation 2|DRUG: Comparator: V505 formulation 2|BIOLOGICAL: Comparator: V505 formulation 3|BIOLOGICAL: Comparator: Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant|BIOLOGICAL: Comparator: Placebo (unspecified)
Geometric mean titers (GMTs) to HPV types contained in the vaccines administered in a 3-dose regimen, 4 weeks post dose 3
Geometric mean titers (GMTs) to HPV types contained in the vaccines administered in a 2-dose regimen, 4 weeks post dose 2
The purpose of this study is to evaluate the safety and immunogenicity of V505 in comparison to GARDASIL (TM)